Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-196 for detection of solid malignancies
NCT03333031Phase 1Terminated
- Sponsor
- Herbert Lyerly
- Start
- Aug 2018
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HS196 in solid tumor, sponsored by Herbert Lyerly. Primary endpoint: Fluorescence at 1 day. Started Aug 2018; status: terminated.
02
Drugs
HS196
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03333031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03333031.